The experiment revealed a decrease in Aβ 1–42 levels in BBS1 treated mouse brains, again demonstrating the ability of mAb BBS1 to inhibit the different cleavage products of APP, especially those considered more toxic in AD. Here, BBS1 is linked to Alzheimer disease.